Comparative Pharmacology
Head-to-head clinical analysis: GONAL F RFF versus MENOPUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GONAL F RFF versus MENOPUR.
GONAL-F RFF vs MENOPUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular growth and maturation and spermatogenesis.
Menotropins (MENOPUR) contain follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity, which stimulate ovarian follicular growth and maturation in women, and spermatogenesis in men with hypogonadotropic hypogonadism.
Subcutaneous injection, initially 75-150 IU once daily for 5-7 days for ovulation induction. For controlled ovarian hyperstimulation, 75-300 IU once daily starting day 2 or 3 of cycle. Dose adjusted based on response.
225 IU subcutaneously or intramuscularly once daily starting on day 2-3 of cycle, adjusted after 5 days based on response; maximum daily dose 450 IU.
None Documented
None Documented
Terminal elimination half-life: approximately 24-30 hours (range 24-36 h) following subcutaneous administration; supports once-daily dosing regimen.
The terminal elimination half-life is approximately 30-40 hours for FSH activity, reflecting the prolonged effect on follicular development; clinical dosing is adjusted based on response.
Renal excretion: approximately 70% of the dose is eliminated in urine as intact hormone and metabolites; fecal excretion is negligible (<5%).
Primarily renal excretion of unchanged drug and metabolites; approximately 80% of a dose is excreted in urine within 24 hours, with the remainder excreted in feces via biliary elimination.
Category C
Category C
Gonadotropin
Gonadotropin